Last reviewed · How we verify
NCT06617117
Central vs Brachial BP, Exercise, and Coronary Artery Disease
NA trial testing High-intensity combined exercise in Coronary Arterial Disease (CAD) in 35 participants. Completed in 15 March 2020.
15 March 2020
Quick facts
| Lead sponsor | Egas Moniz - Cooperativa de Ensino Superior, CRL |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | other |
| Enrollment | 35 |
| Start date | 1 February 2018 |
| Primary completion | 15 March 2020 |
| Estimated completion | 15 March 2020 |
| Sites | 1 location across Portugal |
Drugs / interventions tested
- High-intensity combined exercise
- Moderate-intensity combined exercise
Conditions studied
- Coronary Arterial Disease (CAD) — all drugs for Coronary Arterial Disease (CAD) →
Sponsor
Egas Moniz - Cooperativa de Ensino Superior, CRL — full company profile →
Who can join
Adults 55 to 85, any sex, with Coronary Arterial Disease (CAD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
High blood pressure (BP) is a major risk factor for coronary artery disease (CAD), with 30-70% of CAD patients having elevated BP. The conventional method of measuring BP in the arm (brachial BP) may miss some cases, as individuals can have normal brachial pressure but elevated central systolic pressure, which is a more critical predictor of cardiovascular events. Lowering BP is a key objective in cardiac rehabilitation programs. Examining BP responses after a single bout of exercise could help predict how effectively exercise lowers BP over time. There is a well-established reduction in BP, known as post-exercise hypotension (PEH), which occurs after exercise. This drop is typically around 8 to 9 mmHg and is observed in individuals with and without hypertension. However, it may not occur in people with CAD. The reason for this difference is unclear but may relate to individual variability in exercise responses. No research has closely examined individual responses to PEH in people with CAD, and it remains unclear whether exercise affects central and brachial BP differently, as some medications do. Additionally, exercise intensity may influence the magnitude of the BP reduction post-exercise. Higher-intensity exercise tends to cause a more significant BP drop, both in hypertensive and non-hypertensive individuals, typically within 20 to 60 minutes post-exercise. Therefore, the present study aimed to determine the acute effects of combined exercise at different intensities on central and brachial blood pressure in individuals with and without coronary artery disease. The key research questions were: 1. Is the BP response of central and brachial arteries to acute combined exercise similar? How does coronary artery disease influence these BP responses? Is there individual variability among people with CAD? 2. Does high-intensity exercise, compared to moderate-intensity exercise, produce more pronounced changes in BP in the post-acute exercise period? All participants were asked to: Complete two combined exercise sessions - one moderate- and one high-intensity bout. The order of the sessions was randomly assigned, similar to flipping a coin. BP was measured before and after each acute exercise bout in the laboratory. The researchers compared central and brachial BP responses between exercise intensities (high vs. moderate) and populations (individuals with and without CAD).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Post-exercise differential response of central and brachial blood pressure in patients with coronary artery disease: A randomized crossover trial.
Marôco JL, Angarten V, Pinto R, Santos V, et al · · 2025 · cited 1× · PMID 39982938 · DOI 10.1371/journal.pone.0317212 -
Repeatability of heart-rate variability and baroreflex sensitivity as metrics of cardiac autonomic function during exercise in young females and males.
Gaspar MP, Marôco JL, Cruz L, Laranjo S, et al · · 2026 · PMID 41137920 · DOI 10.1007/s00421-025-06011-w
Verify or expand the search:
- PubMed search for NCT06617117
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Arterial Disease (CAD)
Currently open trials in the same condition.
- NCT07444957 — Safety and Effectiveness of the Crystalline Sirolimus-Eluting Device in Patients With Coronary Artery Disease · recruiting
- NCT06855537 — Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques · Phase 4 · recruiting
- NCT07025148 — Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding · Phase 4 · recruiting
- NCT07093788 — Super High-pressure Balloon Versus Intravascular Lithotripsy to Prepare Severely Calcified Coronary Lesions · NA · recruiting
- NCT07041359 — Pre-trial of Clinical Trial of Traditional Chinese Medicine Treatment for Elderly Patients With Coronary Heart Disease W · Phase 4 · recruiting
Other Egas Moniz - Cooperativa de Ensino Superior, CRL trials
Trials by the same sponsor.
- NCT07533110 — Evaluation Of The Success Rate of NOVAMag® SHIELD In Two Different Advanced Bone Defects: A Randomized Controlled Trial · Phase 4 · recruiting
- NCT07411833 — tDCS for Stress and Burnout in Higher Education · NA · enrolling by invitation
- NCT07190456 — Kinesiophobia vs. Task-Specific Fear: Defining Movement-Related Fear in ACL Reconstruction Patients · NA · recruiting
- NCT07352384 — Evaluation of the Efficacy of Neuromodulation in the Control of Chronic Orofacial Pain · NA · enrolling by invitation
- NCT07079280 — Comparing Vascular Responses to Aerobic Exercise With and Without Blood Flow Restriction in Young and Older Adults · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06617117 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Egas Moniz - Cooperativa de Ensino Superior, CRL
- Last refreshed: 27 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06617117.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing